220 related articles for article (PubMed ID: 34025489)
1. Personality Traits and Cardiotoxicity Arising From Cancer Treatments: An Hypothesized Relationship.
Durosini I; Mazzocco K; Triberti S; Russo GA; Pravettoni G
Front Psychol; 2021; 12():546636. PubMed ID: 34025489
[TBL] [Abstract][Full Text] [Related]
2. Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.
Yang X; Li G; Yang T; Guan M; An N; Yang F; Dai Q; Zhong C; Luo C; Gao Y; Das S; Xing Y; Shang H
Oxid Med Cell Longev; 2020; 2020():4894625. PubMed ID: 33110473
[TBL] [Abstract][Full Text] [Related]
3. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
4. The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.
Reis-Mendes AF; Sousa E; de Lourdes Bastos M; Costa VM
Curr Drug Metab; 2015; 17(1):75-90. PubMed ID: 26526839
[TBL] [Abstract][Full Text] [Related]
5. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).
Pituskin E; Haykowsky M; McNeely M; Mackey J; Chua N; Paterson I
BMC Cancer; 2016 Sep; 16(1):733. PubMed ID: 27629548
[TBL] [Abstract][Full Text] [Related]
7. Why do personality traits predict divorce? Multiple pathways through satisfaction.
Solomon BC; Jackson JJ
J Pers Soc Psychol; 2014 Jun; 106(6):978-96. PubMed ID: 24841100
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
9. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.
Hrynchak I; Sousa E; Pinto M; Costa VM
Drug Metab Rev; 2017 May; 49(2):158-196. PubMed ID: 28393622
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy.
Feroze RA; Leya J; Herron T; Hayek SS
J Cardiovasc Transl Res; 2020 Jun; 13(3):417-430. PubMed ID: 32472498
[TBL] [Abstract][Full Text] [Related]
11. Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies.
López-Fernández T; Thavendiranathan P
Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):487-495. PubMed ID: 28189542
[TBL] [Abstract][Full Text] [Related]
12. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
13. Hypertensive Cardiotoxicity in Cancer Treatment-Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies-Epidemiology, Incidence, and Pathophysiology.
Chung R; Tyebally S; Chen D; Kapil V; Walker JM; Addison D; Ismail-Khan R; Guha A; Ghosh AK
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081013
[TBL] [Abstract][Full Text] [Related]
14. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
[TBL] [Abstract][Full Text] [Related]
15. SEOM clinical guidelines on cardiovascular toxicity (2018).
Virizuela JA; García AM; de Las Peñas R; Santaballa A; Andrés R; Beato C; de la Cruz S; Gavilá J; González-Santiago S; Fernández TL
Clin Transl Oncol; 2019 Jan; 21(1):94-105. PubMed ID: 30627982
[TBL] [Abstract][Full Text] [Related]
16. New Insights About Doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and Dexrazoxane Cytoprotective Effect: Contribution of
Dallons M; Schepkens C; Dupuis A; Tagliatti V; Colet JM
Front Pharmacol; 2020; 11():79. PubMed ID: 32153402
[TBL] [Abstract][Full Text] [Related]
17. Pluripotent Stem Cell Modeling of Anticancer Therapy-Induced Cardiotoxicity.
Lyra-Leite DM; Burridge PW
Curr Cardiol Rep; 2020 Jun; 22(8):56. PubMed ID: 32562096
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.
Khouri MG; Klein MR; Velazquez EJ; Jones LW
Future Cardiol; 2015 Jul; 11(4):471-84. PubMed ID: 26235924
[TBL] [Abstract][Full Text] [Related]
20. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Sadurska E
Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
